Novartis announces Entresto ™ ▼ can be initiated with safety and tolerability in patients...
Novartis presented new data from the TRANSITION study at The British Society of Heart Failure (BSH) 21st Annual Autumn Meeting (29-30 November) in London....
Orion acquires sales & distribution rights for certain EC countries for Stalevo
Orion Corporation and Novartis Pharma AG have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson's disease...
GSK reaches agreement to acquire TESARO
GlaxoSmithKline plc (GSK) and TESARO Inc have entered into a definitive agreement within which GSK will acquire TESARO, an oncology-focused company based in Waltham,...
Birmingham team to lead research into patient experience of cell therapies
Birmingham health researchers, along with industry partners, have been awarded £1.1 million by UK Research & Innovation (UKRI)’s Innovate UK, to investigate patients’ experience...
Merck to present at Citi 2018 Global Healthcare Conference
Merck (MSD outside the United States and Canada), has announced that Robert M. Davis, chief financial offer and executive vice president, Merck Global Services,...
UK pharma pressing ahead with M&As in 2019
The UK pharmaceutical industry is pressing ahead with M&A activity and is geared to weather any disruption due to Brexit, according to the results...
Contraceptive services cuts lead to call for wider choice
Nurses are "ideally placed" to advise on wider choices of contraception to reduce clinic overload and costs, according to a senior contraception and sexual...
Early stage skin cancer immunotherapy Opdivo approved in England
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the reimbursement...
NICE recommends Stivarga ® for advanced unresectable HCC
NICE recommends Stivarga® (regorafenib) for treatment of adult patients with advanced unresectable hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Bayer has announced that...
Vertex announces European Commission approval for KALYDECO®
Vertex announces European Commission approval for KALYDECO ® (ivacaftor) to treat patients with cystic fibrosis aged 12 to <24 months with certain mutations in the...
Latest articles
Maxwellia expand their team with two new appointments
Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator.
BMS & Boston Medical Center announce research collaboration
BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
EC approves KEYTRUDA® as adjuvant therapy
MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...